BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1245 related articles for article (PubMed ID: 14983222)

  • 1. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
    Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
    Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
    Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
    Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin.
    Colucci M; Pentimone A; Binetti BM; Cramarossa M; Piro D; Semeraro N
    Thromb Haemost; 2002 Aug; 88(2):282-7. PubMed ID: 12195701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI).
    Guimarães AH; Barrett-Bergshoeff MM; Criscuoli M; Evangelista S; Rijken DC
    Thromb Haemost; 2006 Sep; 96(3):325-30. PubMed ID: 16953274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII.
    Nielsen VG; Steenwyk BL; Gurley WQ
    J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.
    Mosnier LO; von dem Borne PA; Meijers JC; Bouma BN
    Thromb Haemost; 1998 Nov; 80(5):829-35. PubMed ID: 9843179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The TAFI system. The new role of fibrinolysis].
    Dempfle CE
    Hamostaseologie; 2007 Sep; 27(4):278-81. PubMed ID: 17938767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM; Dosne AM; Kher A; Samama M
    Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.
    Von dem Borne PA; Bajzar L; Meijers JC; Nesheim ME; Bouma BN
    J Clin Invest; 1997 May; 99(10):2323-7. PubMed ID: 9153272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
    Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
    Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats.
    Soni H; Sharma A; Bhatt S; Jain MR; Patel PR
    Pharmacology; 2008; 82(4):304-9. PubMed ID: 18936552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
    Shenkman B; Livnat T; Lubetsky A; Tamarin I; Budnik I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Jul; 23(5):370-8. PubMed ID: 22498982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.
    Mosnier LO; Lisman T; van den Berg HM; Nieuwenhuis HK; Meijers JC; Bouma BN
    Thromb Haemost; 2001 Oct; 86(4):1035-9. PubMed ID: 11686321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y; Scully MF; Ellis V; Kakkar VV
    Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma.
    Neill EK; Stewart RJ; Schneider MM; Nesheim ME
    Anal Biochem; 2004 Jul; 330(2):332-41. PubMed ID: 15203340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
    Trusen B; Ries M; Zenker M; Rauh M; Beinder E; Keuper H; Harms D
    Semin Thromb Hemost; 1998; 24(6):599-604. PubMed ID: 10066156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.